Takeda Pharmaceutical Company Limited (TKPYY)

Other OTC - Other OTC Delayed Price. Currency in USD
23.95+0.12 (+0.52%)
At close: 3:59 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close23.83
Bid0.00 x
Ask0.00 x
Day's Range23.59 - 24.12
52wk Range20.32 - 25.72
1y Target EstN/A
Market Cap37.46B
P/E Ratio (ttm)24.52
Avg Vol (3m)36,126
Dividend & Yield0.87 (3.59%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Market Realistyesterday

    Teva Has a Targeted Strategy to Expand in Major Growth Markets

    In Russia, Teva Pharmaceutical has created a strong portfolio of about 300 products and has been extensively developing its research pipeline.

  • Capital Cube2 days ago

    ETF’s with exposure to Takeda Pharmaceutical Co., Ltd. : September 29, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Takeda Pharmaceutical Co., Ltd. Here are 5 ETF’s with the largest exposure to TKPYY-US. Comparing the performance and risk of Takeda Pharmaceutical Co., Ltd. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • PR Newswire3 days ago

    Additional Interim Data Supporting Long-Term Use of Vedolizumab in Patients with Ulcerative Colitis and Crohn's Disease Published in Journal of Crohn's and Colitis

    OSAKA, Japan, Sept. 29, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") announced that two interim reports from the ongoing, open-label GEMINI long-term safety (LTS) study describing clinical data of long-term Entyvio (vedolizumab) treatment in patients with moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn's disease (CD) have been published in the Journal of Crohn's & Colitis. The data showed that patients with moderately to severely active UC experienced clinical and health-related quality of life (HRQL) improvements with continued vedolizumab treatment. For patients with moderately to severely active CD, the clinical benefits of vedolizumab continued with long-term treatment regardless of prior TNF antagonist exposure.